ArticleJournal of medical virology2026
Global Performance of Human Papillomavirus Typing, Screening, and Evaluation As Assessed Using Proficiency Panels Traceable to International Standards: A Retrospective Analysis, 2008-2024.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Accurate and comparable human papillomavirus (HPV) testing is essential for vaccine research, surveillance, and cervical cancer screening. Since 2008, the WHO HPV Laboratory Network has conducted global HPV proficiency testing traceable to International Standards. Here, we present a retrospective analysis of global HPV genotyping and screening proficiency panel results collected between 2008 and 2024. The HPV genotyping panel consists of 43 blinded samples including HPV6/11, all oncogenic and vaccine-targeted HPV types. A screening panel, launched in 2022, includes 13 blinded samples for cervical screening. Laboratories worldwide test panels using their methods, and results are evaluated at the International HPV Reference Center. Proficiency is defined as absence of false positives and detection of HPV16/18 at 10 IU/µL, and other oncogenic types at 100 IU/µL (genotyping) or 1000 IU/µL (screening). Genotyping panel participation increased from 54 laboratories (2008) to > 130 (2021). Proficiency rose from ~25% to > 80% by 2024, with > 99% correct detection for most genotypes. Optional low-copy challenges (1 IU/µL HPV16/18) were detected by > 95% of laboratories by 2024. Screening panel participation increased from 84 laboratories (2022) to 132 (2024), with proficiency improving from 77% to 95% and > 96% datasets free of false positives. Annual HPV proficiency testing provides global laboratory quality assurance supporting cervical cancer elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.